Armin Spura, PhD,

Dr. Armin Spura has over 25 years of experience in the Life Science industry. For the past four years, he has been leading Crown Bioscience as CEO, a leading translational Contract Research Organization with offices in the US, Europe, and Asia. Dr. Spura joined Crown Bioscience from CareDx, a leader in transplant diagnostics, where he was in charge of the Asia Pacific and Greater China expansion strategy. Before CareDx, he ran the global product commercialization efforts for Wuxi NextCODE’s data analysis and AI solutions. Before Wuxi NextCODE, Dr. Spura held multiple leadership positions at Life Technologies and Thermo Fisher Scientific, where he was General Manager for a China-based joint venture with Da’An Diagnostics, as well as GM for Professional Services for the Genomics Business. Earlier in his career, Dr. Spura helped to grow two start-up companies: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied Biochemistry in Germany and received his PhD in Molecular Biology from Brown University.